Business

IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio

ZUG, Switzerland, January 22, 2026--Galderma (SIX: GALD) will present ten posters with the latest updates from across its broad aesthetic portfolio spanning regenerative biostimulation, HA and neuromodulator treatments at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The company will also showcase its leadership in community education through a number of events including two symposia, a live anatomy workshop, multiple mas

articleGalderma Group AgJanuary 22, 202615/company/galderma-group-n/news/imcas-2026-galderma-showcases-latest-060000833
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio

About this update from Galderma Group Ag

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":823,"height":209,"url":"https://media.zenfs.com/en/business-wire.com/32c681f9c1242988c14aa6d7ae283e0a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_unHR_zFl7JQhwzSnwdPzQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/32c681f9c1242988c14aa6d7ae283e0a","width":823,"height":209},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.QxyjVfGcK2CF1XowDAwYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2NDY7aD00MTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/32c681f9c1242988c14aa6d7ae283e0a","width":823,"height":209}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7","length":324,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane® Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, Restylane Skinboosters™ in smoothing fine lines and wrinkles in the décolletage and Restylane Volyme™ in correcting hollowing of the temples8-11","length":375,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"New data on the innovative neuromodulator Relfydess™ (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12","length":199,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"As a leader in injectable aesthetic innovation, Galderma will showcase its superior science and educational capabilities at the congress","length":136,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1034,"olType":false},{"type":"text","content":"ZUG, Switzerland, January 22, 2026--(BUSINESS WIRE)--Galderma (SIX: GALD) will present ten posters with the latest updates from across its broad aesthetic portfolio spanning regenerative b...

More updates from Galderma Group Ag

IMCASGaldermaParis, FranceRestylane Skinboostershyaluronic acidRestylane Shaypeaesthetic treatmentRestylane LyftSculptratreatment